Citadel Advisors
SMMT icon

Citadel Advisors’s Summit Therapeutics SMMT Stock Holding History

Citadel Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.59M Buy
505,600
+186,800
+59% +$3.02M ﹤0.01% 3320
2025
Q4 		$5.58M Sell
318,800
-278,900
-47% -$5.25M ﹤0.01% 4125
2025
Q3 		$12.3M Sell
597,700
-265,400
-31% -$6.44M ﹤0.01% 2948
2025
Q2 		$18.4M Buy
863,100
+606,500
+236% +$13.8M ﹤0.01% 2248
2025
Q1 		$4.95M Buy
256,600
+17,600
+7% +$353K ﹤0.01% 3887
2024
Q4 		$4.26M Sell
239,000
-88,400
-27% -$1.71M ﹤0.01% 4220
2024
Q3 		$7.17M Buy
327,400
+183,600
+128% +$2.57M ﹤0.01% 3394
2024
Q2 		$1.12M Buy
143,800
+120,400
+515% +$650K ﹤0.01% 6361
2024
Q1 		$96.9K Buy
23,400
+7,600
+48% +$30.2K ﹤0.01% 11406
2023
Q4 		$41.2K Buy
+15,800
New +$32.5K ﹤0.01% 11986
2023
Q2 		– Sell
-9,700
Closed -$17K – 15148
2023
Q1 		$17K Sell
9,700
-67,900
-88% -$185K ﹤0.01% 13176
2022
Q4 		$330K Buy
77,600
+51,300
+195% +$93.3K ﹤0.01% 9102
2022
Q3 		$31K Sell
26,300
-29,400
-53% -$33.3K ﹤0.01% 11898
2022
Q2 		$56K Buy
55,700
+42,600
+325% +$59.7K ﹤0.01% 11859
2022
Q1 		$32K Buy
13,100
+200
+2% +$504 ﹤0.01% 13074
2021
Q4 		$35K Sell
12,900
-6,900
-35% -$33.2K ﹤0.01% 13416
2021
Q3 		$99K Buy
19,800
+7,800
+65% +$56K ﹤0.01% 12885
2021
Q2 		$90K Sell
12,000
-1,800
-13% -$11.8K ﹤0.01% 12998
2021
Q1 		$81K Buy
+13,800
New +$89K ﹤0.01% 12626

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors's SMMT Position: Q1 2026 in Review

Citadel Advisors reduced its Summit Therapeutics (SMMT) stake by 82% in Q1 2026, selling an estimated $32.9M and leaving 441,743 shares worth $8.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3504.

Citadel Advisors first reported a position in SMMT in Q4 2018 and has held it in 17 quarters since. The position peaked at $43.3M in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Citadel Advisors held 441,743 shares of Summit Therapeutics worth $8.38M as of Q1 2026.
  • Citadel Advisors sold 2,033,965 Summit Therapeutics shares in Q1 2026, an estimated $32.9M.
  • Summit Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3504 holding.
  • Citadel Advisors first reported a position in Summit Therapeutics in Q4 2018 and has held it in 17 quarters since.
  • Citadel Advisors's Summit Therapeutics position peaked at $43.3M in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.